Selective Estrogen Receptor Modulators Decrease Reactive Astrogliosis in the Injured Brain: Effects of Aging and Prolonged Depletion of Ovarian Hormones
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
After brain injury, astrocytes acquire a reactive phenotype characterized by a series of morphological and molecular modifications, including the expression of the cytoskeletal protein vimentin. Previous studies have shown that estradiol down-regulates reactive astrogliosis. In this study we assessed whether raloxifene and tamoxifen, two selective estrogen receptor modulators, have effects similar to estradiol in astrocytes. We also assessed whether aging and the timing of estrogenic therapy after ovariectomy influence the action of the estrogenic compounds. Four groups of animals were studied: 1) young rats, ovariectomized at 2 months of age; 2) middle-aged rats, ovariectomized at 8 months of age; 3) aged rats, ovariectomized at 18 months of age; and 4) aged rats, ovariectomized at 2 months and sham operated at 18 months of age. Fifteen days after ovariectomy or sham surgery, animals received a stab wound brain injury and the treatment with the estrogenic compounds. The number of vimentin-immunoreactive astrocytes after injury was significantly higher in the hippocampus of aged rats after a long-term ovariectomy compared with aged animals after a short-term ovariectomy and middle-aged rats. In addition, reactive astrocytes were more numerous in the two groups of aged animals than in young animals. Despite these differences, the estrogenic compounds reduced reactive astrogliosis in all animal groups. These findings indicate that estradiol, raloxifene, and tamoxifen are potential candidates for the control of astrogliosis in young and older individuals and after a prolonged depletion of ovarian hormones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Glia and their cytokines in progression of neurodegeneration
Mrak, R. E., & Griffin, W. S. T. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.05.010 · Cited by 592
Glial expression of estrogen and androgen receptors after rat brain injury
García‐Ovejero, D., Veiga, S., García‐Segura, L. M., & Doncarlos, L. L. (2002) · Journal of Comparative Neurology · doi:10.1002/cne.10325 · Cited by 261
Self-citationNeuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease
Farfara, D., Lifshitz, V., & Frenkel, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00314.x · Cited by 216 · cited 1×
“In addition, the antigliotic effect of estradiol and SERMs on aged females may be particularly relevant for chronic neurodegenerative diseases associated with aging, in which it is suspected that a dysfunction of glial cells may contribute to increased neural damage (43, 44).”
Background
Cited by
The neuroprotective actions of oestradiol and oestrogen receptors
Arevalo, M.-A., Azcoitia, I., & Garcia-Segura, L. M. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3856 · Cited by 480
Self-citationAstrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ãvila, M., Gonzalez, J., El-Bachá, R. S., Báez, E., GarcÃa-Segura, L. M., Jurado Coronel, J. C., Capani, F., Cardona-Gomez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 449
Self-citationDiz-Chaves, Y., Pernía, O., Carrero, P., & Garcia-Segura, L. M. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-71 · Cited by 230
“The effect of prenatal stress was assessed, under basal conditions and after an immune challenge caused by the systemic administration of LPS, in female mice that were ovariectomized to eliminate the neuroprotective and anti-inflammatory action of ovarian hormones [34-36].”
BackgroundSelf-citationActions of estrogens on glial cells: Implications for neuroprotection
Arevalo, M.-A., Santos-Galindo, M., Bellini, M.-J., Azcoitia, I., & Garcia-Segura, L. M. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.10.002 · Cited by 214
Self-citationMetabolic and inflammatory adaptation of reactive astrocytes: role of PPARs
Iglesias, J., Morales, L., & Barreto, G. E. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9833-2 · Cited by 137
“Astrogliosis are broad cellular and functional changes of astrocyte in response to CNS injury or diseases, as these changes are regulated by inter- and intracellular signaling molecules dependent on the severity of the insult [10, 19, 20, 24–28].”
Self-citationAzcoitia, I., Barreto, G. E., & Garcia-Segura, L. M. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100787 · Cited by 125
Self-citationMosquera, L., Colón, J. M., Santiago, J. M., Torrado, A. I., Meléndez, M., Segarra, A. C., Rodríguez-Orengo, J. F., & Miranda, J. D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.03.002 · Cited by 74
“…that Tamoxifen reduces the reactive gliotic response, microglial inflammatory response, infarct volume, increases the number of viable cells in cortex and striatum, and improves the neurobehavioral deficit scores (Barreto et al., 2009; Kimelberg et al., 2003; Liu et al., 2010; Zhang et al., 2005).”
Buwalda, B., & Schagen, S. B. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.12.012 · Cited by 43
Aluminum-induced molecular neurodegeneration: The protective role of genistein and chickpea extract
Wahby, M. M., Mohammed, D. S., Newairy, A. A., Abdou, H. M., & Zaky, A. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.05.044 · Cited by 35
Colón, J. M., Torrado, A. I., Cajigas, Á., Santiago, J. M., Salgado, I. K., Arroyo, Y., & Miranda, J. D. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4111 · Cited by 35
“In addition, this multiactive drug also decreased the level of reactive gliosis generated after SCI or brain trauma.(13,14,47,48) In this study,”
BackgroundTsai, Y.-T., Wang, C.-C., Leung, P.-O., Lin, K.-C., Chio, C.-C., Hu, C.-Y., & Kuo, J.-R. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.02.009 · Cited by 25
“therapy can produce free radical scavenging and antioxidant activity in vitro and in vivo [15,44,45], inhibit excitatory amino acid release via swelling activated anion channels in swollen astrocytes [46], reduce reactive gliosis after a TBI [47], induce an anti-inflammatory response [48], potentiate the basal ac-”
BackgroundColón, J. M., González, P. A., Cajigas, Á., Maldonado, W. I., Torrado, A. I., Santiago, J. M., Salgado, I. K., & Miranda, J. D. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.006 · Cited by 19
“Similar observations were reported by others, when selective estrogen receptor modulators reduced the gliotic response in the injured brain (Arevalo et al., 2012; Barreto et al., 2009).”
Result
Metadata
- Authors
- Barreto, G., Santos-Galindo, M., Diz-Chaves, Y., Pernía, O., Carrero, P., Azcoitia, I., & Garcia-Segura, L. M.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2009-09-24
- Volume
- 150
- Issue
- 11
- Pages
- 5010-5015
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1973563466
- Cited by
- 103
- References
- 5
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.